Emerging Opportunites

Emerging Opportunities

LSI researchers work on a wide range of translational projects: from diagnostics and new drugs to medical equipment, from diabetes and cancer to age related macular degeneration. We always welcome academic and industrial collaborators, and individuals and organizations interested in supporting clinical and scientific advancement in these areas.


 

Research Collaboration / Licensing

Age-Related Macular Degeneration – Polyphosphate (polyP) for the Treatment of Complement-Associated Disorders

Stargardt Macular Degeneration: Linking Drug Discovery to Therapeutic Treatments

Self-Propelled Particles for Hemostatic Applications – Improved Coagulation of Blood in Hemorrhage

A Safer, More Effective Clot-Dissolving Drug: Xai-K

Enhancement of β-cell Survival and Differentiation/Maturation for the Treatment of Diabetes (Type 1 and Type 2)

Universal Antifouling Coating for Medical Implants and Devices

Novel Hollow Microneedle Platform for Efficient and Targeted Delivery of State-of-the-Art Vaccines and Therapeutics

Next-Generation Molecular Diagnostics for Emerging and Re-Emerging Viral Diseases

Concussion Assessment Using Functional Brain Activity

Broad Capture and Removal of Contaminants from Industrial Wastewater

Wipes for Detection and Cleaning of Hazardous Drug Contamination

Targeting Macrophages and Dendritic Cells in Order to Enhance Anti-Cancer Immunity

Customized Nanoparticle Drug Carriers for Nucleic Acid Delivery

X-Chromosome Inactivation: Understanding Epigenetic Regulation, and Sex-Differences

Anti-Inflammatory/Anti-Cancer Antibody Therapeutic for Co-Development

Services

Development of Targeted Peptides to Block Protein-Protein Interactions and Reduce a Protein Level
Company: Primary Peptides

Cardiac Safety Pharmacology, Drug Discovery and Ion Channel Research
Company: Ions Gate

Facility for Infectious Disease and Epidemic Research (CL3)
Facility: FINDER

Find‐It (CG001) Cancer Hotspot Panel – Over 90 Carefully Selected Clinically Actionable Cancer Mutations; from Tumor Sample to Clinical Report in 7 Days
Company: Contextual Genomics

Development and Manufacture of Complex Drug Delivery Systems Using Lipid Nanoparticle Science – Formulation, Analysis and GMP Manufacturing
Company: Transferra

Cryo-Transmission Electron Microscopy (Cryo-TEM) and Particle Sizing for Lipid, Polymeric and Inorganic Nanoparticles (Size, Shape and Morphological Characterization)

Investments

Development of Targeted Peptides to Block Protein-Protein Interactions and Reduce a Protein Level

Novel Hollow Microneedle Platform for Efficient and Targeted Delivery of State-of-the-Art Vaccines and Therapeutics

Targeting Macrophages and Dendritic Cells in Order to Enhance Anti-Cancer Immunity

Anti-Inflammatory/Anti-Cancer Antibody Therapeutic for Co-Development

Contact: Elana Guslitser
Associate Director, Commercialization
e-mail:gelana@mail.ubc.ca
Phone: 604-827-2514
office: 1353